A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-08-02
DOI
10.1038/s41598-019-47802-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model
- (2019) Hanwen Wang et al. Royal Society Open Science
- A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
- (2019) Mohammad Jafarnejad et al. AAPS Journal
- Improving the generation and selection of virtual populations in quantitative systems pharmacology models
- (2018) Theodore R. Rieger et al. PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY
- Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
- (2018) Chung-Han Lee et al. TRENDS IN IMMUNOLOGY
- A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition
- (2017) Chang Gong et al. Journal of the Royal Society Interface
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma
- (2017) Manuel Fankhauser et al. Science Translational Medicine
- Mechanisms and Dynamics of T Cell-Mediated Cytotoxicity In Vivo
- (2017) Stephan Halle et al. TRENDS IN IMMUNOLOGY
- CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: Correlation with clinical outcomes.
- (2017) A. Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential immunotherapy regimens—expect the unexpected
- (2016) Patricio Serra-Bellver et al. LANCET ONCOLOGY
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- Advances in personalized cancer immunotherapy
- (2016) Kazuhiro Kakimi et al. Breast Cancer
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- The human T-cell repertoire grows up
- (2015) James J Moon et al. IMMUNOLOGY AND CELL BIOLOGY
- Somatic mutation in cancer and normal cells
- (2015) I. Martincorena et al. SCIENCE
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- (2015) Leisha A. Emens et al. Cancer Immunology Research
- Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
- (2015) Gregory T. Wurz et al. Therapeutic Advances in Medical Oncology
- A Quantitative Systems Pharmacology Perspective on Cancer Immunology
- (2015) Christina Byrne-Hoffman et al. Processes
- Modeling the T cell immune response: a fascinating challenge
- (2014) Penelope A. Morel et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model
- (2014) Yanguang Cao et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Modeling cancer-immune responses to therapy
- (2014) L. G. dePillis et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
- (2014) Jason Madore et al. Pigment Cell & Melanoma Research
- The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models
- (2013) Sirus Palsson et al. BMC Systems Biology
- Clinical activity of ipilimumab for metastatic uveal melanoma
- (2013) Jason J. Luke et al. CANCER
- Structure and Interactions of the Human Programmed Cell Death 1 Receptor
- (2013) Xiaoxiao Cheng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- How many dendritic cells are required to initiate a T-cell response?
- (2012) S. Celli et al. BLOOD
- Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
- (2012) Esdy N. Rozali et al. Clinical & Developmental Immunology
- The High Cost of Cancer Drugs and What We Can Do About It
- (2012) Mustaqeem Siddiqui et al. MAYO CLINIC PROCEEDINGS
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies
- (2011) Stacey D Finley et al. BMC Systems Biology
- Cancer Immunotherapy Comes of Age
- (2011) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Strength of TCR-Peptide/MHC Interactions and In Vivo T Cell Responses
- (2011) E. Corse et al. JOURNAL OF IMMUNOLOGY
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- Chemokines
- (2010) Steven M. Dubinett et al. CANCER JOURNAL
- Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma
- (2010) Xiaohong Shen et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
- (2009) H. Harlin et al. CANCER RESEARCH
- Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
- (2008) Greg M. Thurber et al. ADVANCED DRUG DELIVERY REVIEWS
- T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation
- (2008) Sarah E Henrickson et al. NATURE IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now